The research team at broker Peel Hunt believes there is a role for intravenous interferon beta-1a (IFN beta-1a) treatments of the type being pioneered by Faron Pharmaceuticals (LON:FARN) as a frontline approach for the effects of Covid.
The commentary followed on from the news that Faron has begun dosing patients for a phase II/III study to assess the efficacy of its IFN beta-1a formulation, Traumakine, in patients with the illness.
The asset is also being developed by Faron for the potential treatment of acute respiratory distress syndrome, severe kidney injury and cardiac protection.
“We agree with that company, that IFNb (Faron’s formulation and treatment paradigm) is a promising asset in the treatment of coronavirus,” Peel Hunt said in a note to clients.
“Despite our successes with vaccines, it is very clear that hospital treatment of coronavirus patients is here to stay and much can still be improved upon in their care/available treatments.”